Literature DB >> 11590382

Chemokine receptor expression profile of eosinophils at inflamed tissue sites: Decreased CCR3 and increased CXCR4 expression by lung eosinophils.

H Nagase1, K Kudo, S Izumi, K Ohta, N Kobayashi, M Yamaguchi, K Matsushima, Y Morita, K Yamamoto, K Hirai.   

Abstract

BACKGROUND: To date, most studies dealing with eosinophil chemokine receptors have used eosinophils isolated from peripheral blood. During the movement of eosinophils from the peripheral blood to inflamed tissue sites, microenvironmental signals might alter their expression of chemokine receptors. However, little is known about the profile of expression of chemokine receptors by eosinophils at inflamed tissue sites in human beings.
OBJECTIVE: The purpose of this study was to determine whether eosinophils that have migrated into inflamed tissues exhibit a profile of chemokine receptor expression that is qualitatively and/or quantitatively different from that of eosinophils in peripheral locations.
METHODS: We studied simultaneously the expression and function of chemokine receptors in eosinophils in both bronchoalveolar lavage fluid (BALF) and peripheral blood specimens of 7 patients with eosinophilic lung diseases.
RESULTS: De novo expression of CCR2, CCR4, and CCR5 was not detected at either the protein or the mRNA level. However, surface expression of CCR3 was decreased and CXCR4 was conversely increased with statistical significance in BALF eosinophils. Moreover, the changes in CCR3 and CXCR4 expression were reflected in the altered migratory response to their ligands. On the other hand, the levels of CXCR1, CXCR2, CXCR3, and CCR1 were virtually unchanged in BALF eosinophils, and these receptors did not have functional significance.
CONCLUSION: Eosinophils at inflamed tissue sites exhibited an expression profile qualitatively similar to that in peripheral locations, except for decreased CCR3 and increased CXCR4 expression. Our results suggest that CCR3 is primarily and CXCR4 is cooperatively involved in eosinophil accumulation at inflamed tissue sites.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11590382     DOI: 10.1067/mai.2001.118292

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  14 in total

Review 1.  Eosinophils in innate immunity: an evolving story.

Authors:  Revital Shamri; Jason J Xenakis; Lisa A Spencer
Journal:  Cell Tissue Res       Date:  2010-11-03       Impact factor: 5.249

2.  AMD3465, a novel CXCR4 receptor antagonist, abrogates schistosomal antigen-elicited (type-2) pulmonary granuloma formation.

Authors:  Jerry S Hu; Christine M Freeman; Valerie R Stolberg; Bo Chin Chiu; Gary J Bridger; Simon P Fricker; Nicholas W Lukacs; Stephen W Chensue
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

3.  Eosinophils utilize multiple chemokine receptors for chemotaxis to the parasitic nematode Strongyloides stercoralis.

Authors:  Louis H Stein; Kevin M Redding; James J Lee; Thomas J Nolan; Gerhard A Schad; James B Lok; David Abraham
Journal:  J Innate Immun       Date:  2009-08-05       Impact factor: 7.349

4.  Novel approach to inhibit asthma-mediated lung inflammation using anti-CD147 intervention.

Authors:  William M Gwinn; Jesse M Damsker; Rustom Falahati; Ifeanyi Okwumabua; Ann Kelly-Welch; Achsah D Keegan; Christophe Vanpouille; James J Lee; Lindsay A Dent; David Leitenberg; Michael I Bukrinsky; Stephanie L Constant
Journal:  J Immunol       Date:  2006-10-01       Impact factor: 5.422

Review 5.  New chemokine targets for asthma therapy.

Authors:  Gilles Garcia; Véronique Godot; Marc Humbert
Journal:  Curr Allergy Asthma Rep       Date:  2005-03       Impact factor: 4.806

6.  Epstein-Barr Virus-induced Gene 2 Mediates Allergen-induced Leukocyte Migration into Airways.

Authors:  Zhong-Jian Shen; Jie Hu; Venkatesh P Kashi; Elizabeth A Kelly; Loren C Denlinger; Kevan Lutchman; Jeffrey G McDonald; Nizar N Jarjour; James S Malter
Journal:  Am J Respir Crit Care Med       Date:  2017-06-15       Impact factor: 21.405

7.  Human airway eosinophils respond to chemoattractants with greater eosinophil-derived neurotoxin release, adherence to fibronectin, and activation of the Ras-ERK pathway when compared with blood eosinophils.

Authors:  Mary Ellen Bates; Julie B Sedgwick; Yiming Zhu; Lin Ying Liu; Rose G Heuser; Nizar N Jarjour; Hirohito Kita; Paul J Bertics
Journal:  J Immunol       Date:  2010-05-21       Impact factor: 5.422

8.  Highly up-regulated CXCR3 expression on eosinophils in mice infected with Schistosoma japonicum.

Authors:  He Li; Hu Chunsong; Cai Guobin; Zhang Qiuping; Li Qun; Zhang Xiaolian; Huang Baojun; Zhang Linjie; Liu Junyan; Jiang Mingshen; Tan Jinquan
Journal:  Immunology       Date:  2004-01       Impact factor: 7.397

Review 9.  What does elevated TARC/CCL17 expression tell us about eosinophilic disorders?

Authors:  Julien Catherine; Florence Roufosse
Journal:  Semin Immunopathol       Date:  2021-05-19       Impact factor: 9.623

Review 10.  Chemokines in allergic airway disease.

Authors:  Clare M Lloyd; Sara M Rankin
Journal:  Curr Opin Pharmacol       Date:  2003-08       Impact factor: 5.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.